Table 3

Outcome characteristics

Author ID	Intervention/Exposure	IPM (%)*	Follow-up times	Loss to follow-up (%)*	PD rehospitalised (%)*	PDM (%)*	Place of PD death	PDM statistics†
All admissions/unspecified infectious admissions
Veirum et al 8		15	Days 1, 14, 30, 91, 182, 365	–		8	77% at home 23% in hospital	63% at 13 w
Moisi et al 9		–	1 year	–	17.7	5.2
Wiens et al 10		4.9	2, 4, 6 months	1.7	16.5	4.9	67% out of hospital 33% in hospital	50% at 4 w
Malnutrition
Hennart et al 14		–	Every year for 5 years	–		15.9		59% at 52 w
Kerac et al 12		23.2	90 days and 1 year	17.2	6.62	24.0		44% at 13 w
Chisti et al 13		8.6	Weekly for 2 weeks then monthly until 6 months	15.0		8.7	80% at home 16% in hospital 4% on transport	59% at 4 w 88% at 9 w
Berkley et al 15	Oral cotrimoxazole prophylaxis	3.4	Once per month until 6 months, then once every 2 months until 12 months	5.3	296 non-fatal admissions	11.1	(32%) in readmission to a study hospital (15%) in other hospitals (53%) in the community
Berkley et al 15	Placebo	3.4		5.1	320 non-fatal admissions	11.1
Grenov et al 32	Probiotics	11.5	At 8–12 weeks	10.4		1.8
Grenov et al 32	Placebo	8.0	At 8–12 weeks	7.9		2.4
Respiratory infection
West et al 33	Hypoxaemia	–	Mean length of follow-up 41 months	36.1		9.6
West et al 33	Non-hypoxaemic	–	Mean length of follow-up 34.1 months	39.3		3.7
Villamor et al 17		3.1	Every 2 weeks for a year then every 4 months Mean duration of follow-up 24.7 months (SD=12.3, median=28.2)	11.4		10.4		80% by 52 w
Ashraf et al 34		0	Every 2 weeks for 3 months	6.4	6.4	1.7
Reddy et al 35	Standard and intensified diagnostic arms analysed together	–	2 and 8 weeks post-enrolment	–		17.4		50% at 2 w ‘postenrolment deaths’; IP or PD not specified
Chhibber et al 16		3.9	180 days	–		2.8		55% at 6 w
Ngari et al 18	Pneumonia	5.6	Every 4 months until 1 year	1.9		3.1	37% in hospital	44% at 13 w 74% at 26 w
Ngari et al 18	No pneumonia	2.4	Every 4 months until 1 year	0.9		1.3
Newberry et al 36	Corticosteroids	27.8	1, 3, 6 months	11.5		19.2
Newberry et al 36	Placebo	52.4	1, 3, 6 months	10.0		35.0
Diarrhoeal diseases
Roy et al 19		–	Monthly for 12 months	–		4		52% at 4 w 70% at 9 w
Stanton et al 37		1.8	At 4–5 months	6.8		2.9
Islam et al 20		14.6	At 6 and 12 weeks	–		7.5		94% at 6 w
Anaemia/Malaria
Zucker et al 24	Anaemia	13	4 and 8 weeks	4.0		18.8
Zucker et al 24	No anaemia; figures include the analysed ‘no-anaemia cohort’ from study plus additional children	9	4 and 8 weeks	4.0		10.3
Biai et al 21	Intervention: improved management and free emergency drugs for malaria, financial incentive	4.6	28 days	3.9		1.8
Biai et al 21	Control	9.4	28 days	4.9		0.9
Phiri et al 25	Severe anaemia	6.4	1, 3, 6, 12, 18 months	17.8	18.1	11.6		71% at 26 w
Phiri et al 25	No anaemia	0	1, 3, 6, 12, 18 months	19.6	9.3	2.7		60% at 26 w
Phiri et al 23	Artemether–lumefantrine	–	1, 3, 6 months	5.0	21.5	2.5		50% at 4 w
Phiri et al 23	Placebo	–	1, 3, 6 months	4.9	24.4	2.3		50% at 9 w
Olupot-Olupot et al 26	Severe anaemia—higher blood transfusion volume (30 mL/kg)	0	28 days postadmission	0		1.3
Olupot-Olupot et al 26	Severe anaemia—standard blood transfusion volume (20 mL/kg)	7.3	28 days postadmission	0		0
Opoka et al 22	Cerebral malaria	12.6	6 months	2.5	3.1	0.6
Opoka et al 22	Severe malarial anaemia	0.4	6 months	3.6	9.4	2.2

*Indicates cumulative rates as of the last follow-up time.
†Indicates specified mortality statistics in regard to per cent of total postdischarges by a certain number of weeks, in relation to entire duration of follow-up.
IP, inpatient; IPM, inpatient mortality; PD, postdischarge; PDM, postdischarge mortality; w,week.